Serotonin: a novel bone mass controller may have implications for alveolar bone
Open Access
- 21 August 2013
- journal article
- editorial
- Published by Springer Nature in Journal of Negative Results in BioMedicine
- Vol. 12 (1) , 12
Abstract
As recent studies highlight the importance of alternative mechanisms in the control of bone turnover, new therapeutic approaches can be envisaged for bone diseases and periodontitis-induced bone loss. Recently, it has been shown that Fluoxetine and Venlafaxine, serotonin re-uptake inhibitors commonly used as antidepressants, can positively or negatively affect bone loss in rat models of induced periodontitis. Serotonin is a neurotransmitter that can be found within specific nuclei of the central nervous system, but can also be produced in the gut and be sequestered inside platelet granules. Although it is known to be mainly involved in the control of mood, sleep, and intestinal physiology, recent evidence has pointed at far reaching effects on bone metabolism, as a mediator of the effects of Lrp5, a membrane receptor commonly associated with Wnt canonical signaling and osteoblast differentiation. Deletion of Lrp5 in mice lead to increased expression of Tryptophan Hydroxylase 1, the gut isoform of the enzyme required for serotonin synthesis, thus increasing serum levels of serotonin. Serotonin, in turn, could bind to HTR1B receptors on osteoblasts and stop their proliferation by activating PKA and CREB.Although different groups have reported controversial results on the existence of an Lrp5-serotonin axis and the action of serotonin in bone remodeling, there is convincing evidence that serotonin modulators such as SSRIs can affect bone turnover. Consequently, the effects of this drug family on periodontal physiology should be thoroughly explored.Keywords
This publication has 70 references indexed in Scilit:
- High-bone-mass-producing mutations in the Wnt signaling pathway result in distinct skeletal phenotypesBone, 2011
- Matrix-embedded cells control osteoclast formationNature Medicine, 2011
- Ontogeny and regulation of the serotonin transporter: Providing insights into human disordersPharmacology & Therapeutics, 2011
- Lrp5 functions in bone to regulate bone massNature Medicine, 2011
- Pharmacological inhibition of gut-derived serotonin synthesis is a potential bone anabolic treatment for osteoporosisNature Medicine, 2010
- A Serotonin-Dependent Mechanism Explains the Leptin Regulation of Bone Mass, Appetite, and Energy ExpenditureCell, 2009
- Regulation of Wnt/β‐catenin signaling by protein kinasesDevelopmental Dynamics, 2009
- TGF-β1–induced migration of bone mesenchymal stem cells couples bone resorption with formationNature Medicine, 2009
- Lrp5 Controls Bone Formation by Inhibiting Serotonin Synthesis in the DuodenumCell, 2008
- Analysis of dishevelled localization and function in the early sea urchin embryoDevelopmental Biology, 2007